Guide · Compounded tirzepatide
A safety-first guide to comparing online compounded tirzepatide providers on oversight, pharmacy transparency, and true monthly cost.
Updated June 1, 2026 · Reviewed by the GLP1 One Telehealth Editorial Team
How do I compare online compounded tirzepatide providers?
Use the same checklist as for any GLP-1: a state-licensed clinician reviews eligibility, the compounding pharmacy is named, the all-in monthly price is clear, you know whether price changes by dose, and shipping and support are included. Compounded tirzepatide is not an FDA-approved finished drug product and is not the same as Mounjaro or Zepbound.
Educational use only. This page is for educational purposes only and does not provide medical advice. Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products and should only be prescribed when clinically appropriate by a licensed healthcare provider.
| Factor | Tirzepatide | Semaglutide |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist |
| Mean weight loss (trials) | ~20–21% (SURMOUNT-1; SURMOUNT-5) | ~15% (STEP 1); 13.7% in SURMOUNT-5 |
| Head-to-head (SURMOUNT-5, 2025) | 20.2% | 13.7% |
| Dosing | Weekly injection | Weekly injection (oral options emerging) |
| Common side effects | Gastrointestinal (nausea, vomiting, diarrhea), mostly during titration | |
Trial figures use FDA-approved products; compounded versions are not FDA-approved finished drug products. Only SURMOUNT-5 is head-to-head.
Compare maintenance-dose cost, not the teaser rate. See independent figures via the compounded tirzepatide pricing guide and deeper detail at TirzepatideReview.
NexLife publishes flat-rate compounded tirzepatide pricing ($186–$215/month, dose-independent) and discloses its pharmacies; see our NexLife review. Compare it against other providers.
With a licensed prescriber and verifiable pharmacy many patients use it, but it is not an FDA-approved finished drug product; a clinician should assess eligibility.
No. It is not an FDA-approved finished product and is not the same as brand-name tirzepatide.
Head-to-head trial data (SURMOUNT-5, 2025) showed greater average weight loss with tirzepatide, but the right choice is individual and clinical.